Array BioPharma, Inc. (NASDAQ:ARRY)
CAPS Rating:
A biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases.
RSS Headlines
Fool UK
Recs
ARRY has a too high valuation compared to its sales potential. It is also one of the most loss making companies. It may go bankrupt.